Opinion|Videos|March 26, 2024
Balancing Toxicity Concerns with Achieving Adequate Response in Myelofibrosis
Author(s)Stephen Oh, MD, PhD
An overview of how toxicity concerns are balanced with the goal of achieving adequate response in patients with myelofibrosis who receive sequential therapies such as JAK inhibitors.
Advertisement
Episodes in this series
Case: A 63-Year-Old Man with Myelofibrosis
Clinical Presentation:
- A 63-year-old man recently diagnosed with primary MF and initiated on 10 mg BID ruxolitinib.
- PMH: type 2 diabetes, hypercholesteremia, and hypertension, squamous cell carcinoma (SCC)
Follow up and Clinical Workup at 3 Months:
- Exam: night sweats improved.
- Labs: Hb 7.8 g/dL; Plt 80 x 109/L (previously 135k) stabilized.
- Some spleen reduction.
- Patient receives ~1 unit RBC per month.
Follow up and Clinical Workup at 6 Months:
- Patient reports complaints of fatigue and abdominal pain.
- Labs: Plt 55 x 109/L; Hgb 6.8 g/dL
- Patient now receives 2 units RBC per month.
- Experienced recurrence of SCC.
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia whose quality of life is impaired even as her platelet count recovers.
Andrew T. Kuykendall, MD, explains the significance of the FDA approval of rusfertide for polycythemia vera.
Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Adjuvant Atezolizumab Plus Chemo for dMMR Colon Cancer
2
Hormone Receptor Status, HER2DX Score Predict Response to Neoadjuvant THP
3
Adding Quality of Life to Treatment Goals in Immune Thrombocytopenia
4
Prostate and Rare Cancer Agents Nab FDA Fast Track Status
5